ArticleScientific reports2025
Integrated genomic-transcriptomic analysis of clavulanic acid production in differentially productive Streptomyces clavuligerus strains.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Clavulanic acid (CA) is a specific metabolite that inhibits β-lactamases, which inactivate β-lactam antibiotics, therefore reinstating the activity of β-lactams against β-lactamase-producing pathogens, and surmounting β-lactam resistance. While extensive efforts have been made to optimize CA production through random mutagenesis, these approaches often introduce deleterious mutations, limiting further yield improvements. In this study, whole-genome sequencing, time-resolved transcriptomics, and independent component analysis (ICA)-based gene co-expression network analysis were employed to elucidate the genetic and transcriptomic factors underlying enhanced CA production in mutant Streptomyces clavuligerus strains developed through ultraviolet-induced random mutagenesis. By analyzing strains with varying CA productivities and correlating genomic and transcriptomic changes, we identified multiple candidate mutations, key transcriptional regulators, and metabolic pathways influencing CA yield. Notable findings include large plasmid deletions, an enrichment of mutations in secondary metabolite biosynthesis and regulatory genes, and metabolic shifts redirecting amino acid and carbon flux toward CA biosynthetic pathways. ICA revealed gene modules directly associated with CA biosynthesis, precursor supply, and transcriptional regulation. This integrative approach generated a comprehensive paired genomic-transcriptomic dataset for CA production. The insights gained offer targeted strategies for rational strain engineering, advancing more efficient and sustainable antibiotic production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.